Blood test to predict targeted therapy response in colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study is developing a blood test that looks at DNA signals to see if certain targeted therapies will work for people with metastatic colorectal cancer. It may help doctors choose the right treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with metastatic colorectal cancer (cancer that has spread).
- You have received treatment with cetuximab, panitumumab, or bevacizumab (targeted therapy).
- You had a blood sample taken before starting that treatment for this study.
- You have had scans to measure how your tumor responded to treatment.
- Your tumor has been tested for RAS and BRAF gene mutations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test to look for specific DNA changes that may help predict how well chemotherapy works in people with metastatic colorectal cancer. The goal is to find markers that could guide future treatment decisions.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
This study tests if checking your blood for tumor DNA after two rounds of chemotherapy can help doctors decide if they can safely lower the dose or switch your treatment. It's for people with advanced colorectal cancer that started on the left side or in the rectum.
This trial uses a blood test to track changes in cancer-related DNA markers (methylation) to see how well treatment is working. It is for people with colorectal or small intestinal cancer that has not spread and who have not yet started treatment.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.